- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Mammary Gland.
Displaying page 1 of 1.
| EudraCT Number: 2013-001249-15 | Sponsor Protocol Number: 314-12-401 | Start Date*: 2013-11-07 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Otsuka Novel Products GmbH | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Two-Part Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients with Advanced Cancers that are Poorly Responsive ... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: • Advanced prostate cancer • Advanced epithelial ovarian cancer, advanced squamous cell carcinoma of the cervix, advanced breast cancer, endometrial cancer, and salivary gland cancer that are p... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-000510-59 | Sponsor Protocol Number: 01012014 | Start Date*: 2014-08-11 | |||||||||||
| Sponsor Name:Dept of Plastic Surgery, Breast Surgery & Burns | |||||||||||||
| Full Title: Fat transplantation enriched with ex vivo expanded adipose-derived autologous mesenchymal stem cells in reconstruction of the breast. | |||||||||||||
| Medical condition: The study will include participants with breast hypoplasia (International Classification of Diseases-10: DQ 838A). | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-001016-51 | Sponsor Protocol Number: 05-UTROGEL-01 | Start Date*: 2006-02-28 |
| Sponsor Name:Karolinska Hospital | ||
| Full Title: In vivo effects of transdermal Estradiol+ oral Progesterone vs oral Conjugated Equine Estrogens + MedroxyProgesteroneAcetate on normal human breast cells proliferation: a randomized comparative study | ||
| Medical condition: Menopausal symptoms | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-000885-13 | Sponsor Protocol Number: UC-0105/1303 | Start Date*: 2013-07-31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with metastatic or unresectable locally advanced malignancies harboring specific genomic alterations regarding the biological crizotinib targets, and who are no more amenable to curative t... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-005168-14 | Sponsor Protocol Number: UMCN-AKF11.01 | Start Date*: 2012-05-14 | ||||||||||||||||
| Sponsor Name:Radboud University Nijmegen Medical Centre | ||||||||||||||||||
| Full Title: Lean Body Mass as a determinant of docetaxel pharmacokinetics and toxicity (LEANDOC) | ||||||||||||||||||
| Medical condition: Exposure and toxicity of docetaxel treatment with patients with breast or metastatic castration-resistant prostate carcinoma. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-002667-53 | Sponsor Protocol Number: 213409 | Start Date*: 2021-08-23 | |||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||||||||||||
| Full Title: An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and are Judged by the Investigator to Benefit... | |||||||||||||||||||||||
| Medical condition: advanced ovarian, breast, or prostate cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: AT (Trial now transitioned) FR (Trial now transitioned) DK (Completed) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2019-004730-42 | Sponsor Protocol Number: IQVIA-ODYS-001-LZA45541 | Start Date*: 2022-10-24 | |||||||||||||||||||||||||||||||
| Sponsor Name:IQVIA RDS FRANCE SAS | |||||||||||||||||||||||||||||||||
| Full Title: Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in c... | |||||||||||||||||||||||||||||||||
| Medical condition: Long term potential effect of repeated exposure to either a linear or a macrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 in motor and cognitive function among ne... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) IT (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-022278-15 | Sponsor Protocol Number: D0810C00042 | Start Date*: 2010-10-25 | ||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||
| Full Title: A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy And Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have A Confir... | ||||||||||||||||||||||||||||
| Medical condition: Patients With Advanced Cancers Who Have A Confirmed Genetic BRCA1 And/Or BRCA2 Mutation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) SE (Completed) ES (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2021-006227-17 | Sponsor Protocol Number: D8410C00001 | Start Date*: 2022-09-14 | |||||||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||||||||||||
| Full Title: A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy an... | |||||||||||||||||||||||||||||||||
| Medical condition: Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D Mdoule 2:... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: SE (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-003432-37 | Sponsor Protocol Number: A005D-E01-201 | Start Date*: 2018-02-06 | |||||||||||||||||||||||||||||||
| Sponsor Name:Advanced Accelerator Applications International SA | |||||||||||||||||||||||||||||||||
| Full Title: Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide Receptor | |||||||||||||||||||||||||||||||||
| Medical condition: Malignancies known to overexpress Gastrin-Releasing Peptide Receptors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: AT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-004398-28 | Sponsor Protocol Number: AA01 | Start Date*: 2016-06-17 | ||||||||||||||||||||||||||
| Sponsor Name:Medical Research Council Clinical Trials Unit at UCL [...] | ||||||||||||||||||||||||||||
| Full Title: A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. | ||||||||||||||||||||||||||||
| Medical condition: Cancer (breast, colorectal, gastro-oesophageal and prostate) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2019-003777-26 | Sponsor Protocol Number: D0817C00098 | Start Date*: 2020-05-27 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||||||||||||
| Full Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment | ||||||||||||||||||||||||||||||||||||||
| Medical condition: BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BG (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) DK (Completed) BE (Trial now transitioned) SE (Trial now transitioned) FI (Completed) PT (Trial now transitioned) SI (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-004426-10 | Sponsor Protocol Number: MO28072 | Start Date*: 2012-05-11 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with cancers (excluding melanoma and papillary thyroid cancer) harboring BRAF V600 mutations as identified by the routinely performed mutation analysis assays at each individual partici... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) ES (Completed) DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-001699-39 | Sponsor Protocol Number: HER117158 | Start Date*: 2015-03-11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Research Development Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with adva... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Subjects with advanced HER3-positive solid tumors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
